ISIS 2503
CDR0000067701
Phase 2 small_molecule completed
Quick answer
ISIS 2503 for Pancreatic Cancer is a Phase 2 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IONIS PHARMACEUTICALS INC
- Indication
- Pancreatic Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed